OVCA (CA 125) second generation: Technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease

Tumori

Volumn 83, Issue 2, 1997, Pages 594-598

  Cioffi, Michele ^a   Fratta, Mario ^a   Gazzerro, Patrizia ^a   Di Finizio, Bruno ^a   Tucci, Aniello ^a   Molinari, Anna Maria ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

CA125 first and second generation; Liver disease; Ovarian tumor marker; Pregnancy

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; LIVER DISEASE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY DISEASE; PERFORMANCE; PREGNANCY; ARTICLE; BLOOD; IMMUNOLOGY; OVARY TUMOR; REFERENCE VALUE;

CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; LIVER DISEASES; OVARIAN DISEASES; OVARIAN NEOPLASMS; PREGNANCY; REFERENCE VALUES;

EID: 0030610969     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169708300223     Document Type: Conference Paper

References (22)

1. Avall-Lundqvist E.H., Sjovall K., Nilsson B.R., Eneroth P.H.: Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA125 in cervical carcinoma. Eur. J. Cancer, 28: 1695-1702, 1992.
2. Armitage P.: Statistica medica. Nuovi Saggi Scientifici Feltrinelli, Milano, 1988.
3. Bast R.C., Feeney M., Lazarus H., Nadler L.K., Colvin R.B., Knapp R.C.: Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest., 68: 1331-1337, 1981.
4. Bast R.C., Knapp R.C.: Use of CA125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol., 19: 354-355, 1985.
5. Bergmann J.F., Beaugrand M., Labadie H., Birdart J.M., Bohnon C.: CA125 (Ovarian Tumor-Associated Antigen) in ascitic liver diseases. Clin. Chim. Acta, 155: 163-166, 1986.
6. Brumsted J.R., Nakajima S.T., Badger G., Riddick D.H., Gibson M.: Serum concentration of CA125 during the first trimester of normal and abnormal pregnancies. J. Reprod. Med., 35: 499-502, 1990.
7. Collazos J., Genolla J., Ruibal A.: CA125 serum levels in patients with non-neoplastic liver disease. A clinical and laboratory study. Scand. J. Clin. Lab. Invest., 52: 201-206, 1992.
8. Collazos J., Diaz F.: Cancer antigen 125 in patients with liver diseases. Clin. Chem., 38: 1188-1189, 1992.
9. Cosmi E.V., Atlante G., Donadio C., Mariani L., Barbati A.: Evaluation of second generation CA125 assay. Eur. J. Obstet. Gynecol. Reprod. Biol., 58: 73-76, 1995.
10. De Bruijn H.W., Duk M.J.: CA125 in endometrial cancer: prognosis and survival. Anticancer Res., 13, 5B: 1654-1657, 1993.
11. Grover S., Koh H., Weideman P., Quinn M.A.: The effect of the menstrual cycle on serum CA125 levels: a population study. Am. J. Obstet. Gynecol., 167: 1379-1381, 1992.
12. Hardardottir H., Parmley T.H., Quirck J.G., Sanders M.M., Miller F.C., O'Brien T.J.: Distribution of CA125 in embryonic tissues and adult derivatives of the fetal periderm. Am. J. Obstet. Gynecol., 163: 1925-1931, 1990.
13. Hogberg T., Kagedal B.: Long-term follow-up of ovarian cancer with monthly determinations of serum CA125. Ginecol. Oncol., 46: 191-198, 1992.
14. Hornstein M.D., Harlow B.L., Thomas P.P., Check J.H.: Use of a new CA125 assay in the diagnosis of endometriosis. Hum. Reprod., 10: 932-934, 1995.
15. Kabawat S.E., Bast R.C., Bhan A.K., Welch W.R., Knapp R.C., Colvin R.B.: Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC 125. Int. J. Gynecol. Pathol., 2: 275-285, 1983.
16. Lehtovirta P., Viinikka L., Ylikorkala O.: Comparison betweeen squamous cell carcinoma-associated CA125 and CA125 in patients with carcinoma of the cervix. Gynecol. Oncol., 37: 276-278, 1990.
17. Lehtovirta P., Apter D., Stenman U.H.: Serum CA125 levels during the menstrual cycle. Br. J. Obstet. Gynecol., 97: 930-933, 1990.
18. Makar A.P., Kristensen G.B., Brmer O.P., Trope C.G.: Is serum CA125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer. Gynecol. Oncol., 49: 3-7, 1993.
19. Marechal F., Berthiot G., Kritly T., Legrand M.G., Deltour G., Cattan A.: Analysis of CA125 levels in the sera of patients with non-ovarian carcinomas and non-malignant diseases. Anticancer Res., 9: 593-598, 1989.
20. Maughan T.S., Fish R.G., Shelley M., Jasani B., Williams G.T., Adams M.: Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary. Gynecol. Oncol., 30: 342-346, 1988.
21. Niloff J.M., Klug L., Schaetzl E., Zurawski V.R., Bast R.C.: Elevation of serum CA125 in carcinomas of the Fallopian tube, endometrium and endocervix. Am. J. Obstet. Gynecol., 148: 1057-1058, 1984.
22. Smikle C.B., Lunt C.C., Hankins G.D.: Clinical predictors in the evaluation of a pelvic mass. Mil. Med., 160: 233-235, 1995.